| 1 | Prognostic relevance of baseline exercise stress test in <i>RYR2</i>-related CPVT | 2.0 | 4 | Citations (PDF) |
| 2 | The diagnostic role of pharmacological provocation testing in cardiac electrophysiology: a clinical consensus statement of the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC, the ESC Working Group on Cardiovascular Pharmacotherapy, the Association of European Paediatric and Congenital Cardiology (AEPC), the Paediatric & Congenital Electrophysiology Society (PACES), the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhyth | 2.0 | 15 | Citations (PDF) |
| 3 | Genotype-Specific Outcomes of Desmosomal Cardiomyopathies | 18.1 | 4 | Citations (PDF) |
| 4 | A Clinical Diagnostic Test for Calcium Release Deficiency Syndrome | 16.6 | 14 | Citations (PDF) |
| 5 | Nonmodifiable Risk Factors Predict Outcomes in Brugada Syndrome | 2.3 | 9 | Citations (PDF) |
| 6 | Value of 3D echocardiography in the diagnosis of arrhythmogenic right ventricular cardiomyopathy | 1.4 | 9 | Citations (PDF) |
| 7 | Characteristics of Patients with Spontaneous Versus Drug-Induced Brugada Electrocardiogram: Sub-Analysis From the SABRUS | 6.1 | 6 | Citations (PDF) |
| 8 | Prevention of Sudden Death and Management of Ventricular Arrhythmias in Arrhythmogenic Cardiomyopathy | 1.0 | 3 | Citations (PDF) |
| 9 | Characterization of Skeletal Muscle Biopsy and Derived Myoblasts in a Patient Carrying Arg14del Mutation in Phospholamban Gene | 4.7 | 5 | Citations (PDF) |
| 10 | RyR2 C-terminal Truncating Variants Identified in Patients with Arrhythmic Phenotypes Exert a Dominant Negative Effect through Formation of Wildtype-truncation Heteromers | 3.8 | 1 | Citations (PDF) |
| 11 | Independent validation and clinical implications of the risk prediction model for long QT syndrome (1-2-3-LQTS-Risk) | 2.0 | 49 | Citations (PDF) |
| 12 | Cardiac ryanodine receptors: is a severe loss-of-function not so severe after all? | 2.0 | 2 | Citations (PDF) |
| 13 | Independent validation and clinical implications of the risk prediction model for long QT syndrome (1-2-3-LQTS-Risk): comment—Authors' reply | 2.0 | 8 | Citations (PDF) |
| 14 | Rare Variation in Drug Metabolism and Long QT Genes and the Genetic Susceptibility to Acquired Long QT Syndrome | 2.9 | 9 | Citations (PDF) |
| 15 | Genome-wide association analyses identify new Brugada syndrome risk loci and highlight a new mechanism of sodium channel regulation in disease susceptibility | 25.2 | 129 | Citations (PDF) |
| 16 | Outcomes of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia Treated With β-Blockers | 11.2 | 63 | Citations (PDF) |
| 17 | Arrhythmic risk prediction in arrhythmogenic right ventricular cardiomyopathy: external validation of the arrhythmogenic right ventricular cardiomyopathy risk calculator | 2.2 | 69 | Citations (PDF) |
| 18 | TRPM4 inhibition by meclofenamate suppresses Ca2+-dependent triggered arrhythmias | 2.2 | 28 | Citations (PDF) |
| 19 | 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death | 2.2 | 2,289 | Citations (PDF) |
| 20 | Assessment of absolute risk of life-threatening cardiac events in long QT syndrome patients | 2.5 | 7 | Citations (PDF) |
| 21 | Enhancing rare variant interpretation in inherited arrhythmias through quantitative analysis of consortium disease cohorts and population controls | 4.2 | 89 | Citations (PDF) |
| 22 | Cardiac ryanodine receptor calcium release deficiency syndrome | 12.5 | 100 | Citations (PDF) |
| 23 | Identification of loss-of-function RyR2 mutations associated with idiopathic ventricular fibrillation and sudden death | 3.8 | 36 | Citations (PDF) |
| 24 | Precision Medicine in Catecholaminergic Polymorphic Ventricular Tachycardia | 2.3 | 60 | Citations (PDF) |
| 25 | ESC CONGRESS 2020—the digital experience: expanding the reach of the society | 2.2 | 1 | Citations (PDF) |
| 26 | Management of Congenital Long-QT Syndrome: Commentary From the Experts | 6.1 | 16 | Citations (PDF) |
| 27 | Genotype-Phenotype Correlation of
<i>SCN5A</i>
Genotype in Patients With Brugada Syndrome and Arrhythmic Events: Insights From the SABRUS in 392 Probands | 2.9 | 15 | Citations (PDF) |
| 28 | Additional diagnostic value of cardiac magnetic resonance feature tracking in patients with biopsy-proven arrhythmogenic cardiomyopathy | 2.2 | 11 | Citations (PDF) |
| 29 | Inherited conditions of arrhythmia: translating disease mechanisms to patient management | 5.5 | 7 | Citations (PDF) |
| 30 | An International Multicenter Evaluation of Inheritance Patterns, Arrhythmic Risks, and Underlying Mechanisms of
<i>CASQ2</i>
-Catecholaminergic Polymorphic Ventricular Tachycardia | 18.1 | 75 | Citations (PDF) |
| 31 | Cell identity and nucleo-mitochondrial genetic context modulate OXPHOS performance and determine somatic heteroplasmy dynamics | 10.9 | 43 | Citations (PDF) |
| 32 | Stabilizer Cell Gene Therapy | 6.1 | 18 | Citations (PDF) |
| 33 | ESC Core Curriculum for the Cardiologist | 2.2 | 60 | Citations (PDF) |
| 34 | Transethnic Genome-Wide Association Study Provides Insights in the Genetic Architecture and Heritability of Long QT Syndrome | 18.1 | 129 | Citations (PDF) |
| 35 | Desmoplakin Cardiomyopathy, a Fibrotic and Inflammatory Form of Cardiomyopathy Distinct From Typical Dilated or Arrhythmogenic Right Ventricular Cardiomyopathy | 18.1 | 414 | Citations (PDF) |
| 36 | Association of Hydroxychloroquine With QTc Interval in Patients With COVID-19 | 18.1 | 36 | Citations (PDF) |
| 37 | Warning: not all carriers of pathogenic mutations in desmosomal genes should follow the same medical advices! | 5.5 | 1 | Citations (PDF) |
| 38 | An International Multicenter Evaluation of Type 5 Long QT Syndrome | 18.1 | 54 | Citations (PDF) |
| 39 | Continued misuse of orphan drug legislation: a life-threatening risk for mexiletine | 2.2 | 20 | Citations (PDF) |
| 40 | Natural History and Risk Stratification in Andersen-Tawil Syndrome Type 1 | 2.3 | 65 | Citations (PDF) |
| 41 | Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era | 2.2 | 788 | Citations (PDF) |
| 42 | Enhancement of Cardiac Store Operated Calcium Entry (SOCE) within Novel Intercalated Disk Microdomains in Arrhythmic Disease | 3.4 | 37 | Citations (PDF) |
| 43 | Ethnic differences in patients with Brugada syndrome and arrhythmic events: New insights from Survey on Arrhythmic Events in Brugada Syndrome | 2.7 | 30 | Citations (PDF) |
| 44 | 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summary | 2.7 | 173 | Citations (PDF) |
| 45 | Severe Cardiac Dysfunction and Death Caused by Arrhythmogenic Right Ventricular Cardiomyopathy Type 5 Are Improved by Inhibition of Glycogen Synthase Kinase-3β | 18.1 | 87 | Citations (PDF) |
| 46 | Efficacy and Limitations of Quinidine in Patients With Brugada Syndrome | 6.1 | 26 | Citations (PDF) |
| 47 | 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy | 2.7 | 689 | Citations (PDF) |
| 48 | Characterization and Management of Arrhythmic Events in Young Patients With Brugada Syndrome | 2.3 | 65 | Citations (PDF) |
| 49 | Time-to-first appropriate shock in patients implanted prophylactically with an implantable cardioverter-defibrillator: data from the Survey on Arrhythmic Events in BRUgada Syndrome (SABRUS) | 2.0 | 20 | Citations (PDF) |
| 50 | International Triadin Knockout Syndrome Registry | 2.9 | 45 | Citations (PDF) |
| 51 | Genetic risk stratification in cardiac arrhythmias | 1.6 | 9 | Citations (PDF) |
| 52 | Interplay Between Genetic Substrate, QTc Duration, and Arrhythmia Risk in Patients With Long QT Syndrome | 2.3 | 195 | Citations (PDF) |
| 53 | Fever-related arrhythmic events in the multicenter Survey on Arrhythmic Events in Brugada Syndrome | 2.7 | 83 | Citations (PDF) |
| 54 | Profile of patients with Brugada syndrome presenting with their first documented arrhythmic event: Data from the Survey on Arrhythmic Events in BRUgada Syndrome (SABRUS) | 2.7 | 73 | Citations (PDF) |
| 55 | CardioVAI: An automatic implementation of ACMG-AMP variant interpretation guidelines in the diagnosis of cardiovascular diseases | 4.5 | 43 | Citations (PDF) |
| 56 | Gender differences in patients with Brugada syndrome and arrhythmic events: Data from a survey on arrhythmic events in 678 patients | 2.7 | 78 | Citations (PDF) |
| 57 | Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: Position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE | 2.0 | 89 | Citations (PDF) |
| 58 | Allele-Specific Silencing of Mutant mRNA Rescues Ultrastructural and Arrhythmic Phenotype in Mice Carriers of the R4496C Mutation in the Ryanodine Receptor Gene (
<i>RYR2</i>
) | 13.2 | 94 | Citations (PDF) |
| 59 | Genetic causes of sudden cardiac death in the young | 1.6 | 10 | Citations (PDF) |
| 60 | Silvia Priori MD PhD | 2.2 | 0 | Citations (PDF) |
| 61 | Hydroquinidine Prevents Life-Threatening Arrhythmic Events in Patients With Short QT Syndrome | 2.3 | 88 | Citations (PDF) |
| 62 | Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: Position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE | 2.0 | 210 | Citations (PDF) |
| 63 | Beta-blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: Are all beta-blockers equivalent? | 2.7 | 110 | Citations (PDF) |
| 64 | Age of First Arrhythmic Event in Brugada Syndrome | 6.1 | 74 | Citations (PDF) |
| 65 | Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia | 11.2 | 164 | Citations (PDF) |
| 66 | Is There a Role for Genetics in the Prevention of Sudden Cardiac Death? | 2.1 | 13 | Citations (PDF) |
| 67 | Arrhythmogenic Right Ventricular Cardiomyopathy | 2.3 | 172 | Citations (PDF) |
| 68 | Adeno-associated virus-mediated CASQ2 delivery rescues phenotypic alterations in a patient-specific model of recessive catecholaminergic polymorphic ventricular tachycardia | 8.5 | 58 | Citations (PDF) |
| 69 | Programmed Ventricular Stimulation for Risk Stratification in the Brugada Syndrome | 18.1 | 237 | Citations (PDF) |
| 70 | Guía ESC 2015 sobre el tratamiento de pacientes con arritmiasventriculares y prevención de la muerte súbita cardiaca | 1.1 | 23 | Citations (PDF) |
| 71 | 2015 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death | 0.5 | 58 | Citations (PDF) |
| 72 | Gene-Specific Therapy With Mexiletine Reduces Arrhythmic Events in Patients With Long QT Syndrome Type 3 | 2.3 | 235 | Citations (PDF) |
| 73 | Clinical Challenges in Catecholaminergic Polymorphic Ventricular Tachycardia | 0.9 | 46 | Citations (PDF) |
| 74 | R4496C RyR2 mutation impairs atrial and ventricular contractility | 2.4 | 23 | Citations (PDF) |
| 75 | Genetics of Sudden Cardiac Death | 13.2 | 257 | Citations (PDF) |
| 76 | Use of Whole Exome Sequencing for the Identification of
<i>I</i>
<sub>to</sub>
‐Based Arrhythmia Mechanism and Therapy | 4.0 | 16 | Citations (PDF) |
| 77 | Unusual retrospective prenatal findings in a male newborn with Timothy syndrome type 1 | 1.6 | 17 | Citations (PDF) |
| 78 | Gene therapy to treat cardiac arrhythmias | 35.7 | 52 | Citations (PDF) |
| 79 | 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death | 2.0 | 659 | Citations (PDF) |
| 80 | 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death | 2.2 | 3,494 | Citations (PDF) |
| 81 | The usual suspects in sudden cardiac death of the young: a focus on inherited arrhythmogenic diseases | 1.8 | 37 | Citations (PDF) |
| 82 | The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology | 2.2 | 88 | Citations (PDF) |
| 83 | Genetically induced dysfunctions of Kir2.1 channels: implications for short QT3 syndrome and autism–epilepsy phenotype | 2.9 | 76 | Citations (PDF) |
| 84 | Subclinical Abnormalities in Sarcoplasmic Reticulum Ca2+ Release Promote Eccentric Myocardial Remodeling and Pump Failure Death in Response to Pressure Overload | 2.3 | 50 | Citations (PDF) |
| 85 | Missense Mutations in Plakophilin-2 Cause Sodium Current Deficit and Associate With a Brugada Syndrome Phenotype | 18.1 | 324 | Citations (PDF) |
| 86 | Congenital Long QT Syndrome Type 3 | 1.0 | 3 | Citations (PDF) |
| 87 | Single Delivery of an Adeno-Associated Viral Construct to Transfer the
<i>CASQ2</i>
Gene to Knock-In Mice Affected by Catecholaminergic Polymorphic Ventricular Tachycardia Is Able to Cure the Disease From Birth to Advanced Age | 18.1 | 111 | Citations (PDF) |
| 88 | 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy | 2.2 | 4,009 | Citations (PDF) |
| 89 | Novel Insight Into the Natural History of Short QT Syndrome | 2.3 | 216 | Citations (PDF) |
| 90 | Executive Summary: HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes | 2.7 | 180 | Citations (PDF) |
| 91 | HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes | 2.7 | 1,783 | Citations (PDF) |
| 92 | Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes | 2.0 | 528 | Citations (PDF) |
| 93 | Abnormal Propagation of Calcium Waves and Ultrastructural Remodeling in Recessive Catecholaminergic Polymorphic Ventricular Tachycardia | 13.2 | 46 | Citations (PDF) |
| 94 | Induced pluripotent stem cell–derived cardiomyocytes in studies of inherited arrhythmias | 10.6 | 58 | Citations (PDF) |
| 95 | A Clinical Approach to Inherited Arrhythmias | 3.8 | 28 | Citations (PDF) |
| 96 | Sudden Cardiac Death and Genetic Ion Channelopathies | 18.1 | 143 | Citations (PDF) |
| 97 | Genetics of ion-channel disorders | 1.6 | 37 | Citations (PDF) |
| 98 | The European CRT Survey: 1 year (9–15 months) follow‐up results | 7.4 | 91 | Citations (PDF) |
| 99 | Genetics and Arrhythmias: Diagnostic and Prognostic Applications | 0.5 | 9 | Citations (PDF) |
| 100 | Genética y arritmias: aplicaciones diagnósticas y pronósticas | 1.1 | 36 | Citations (PDF) |
| 101 | Inherited calcium channelopathies in the pathophysiology of arrhythmias | 35.7 | 172 | Citations (PDF) |
| 102 | Risk Stratification in Brugada Syndrome | 2.3 | 560 | Citations (PDF) |
| 103 | Flecainide and Antiarrhythmic Effects in a Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia | 7.1 | 11 | Citations (PDF) |
| 104 | Risk Stratification in the Long QT Syndrome | 1.0 | 26 | Citations (PDF) |
| 105 | The European Cardiac Resynchronization Therapy Survey: comparison of outcomes between de novo cardiac resynchronization therapy implantations and upgrades | 7.4 | 103 | Citations (PDF) |
| 106 | Role of calmodulin kinase in catecholaminergic polymorphic ventricular tachycardia | 2.7 | 7 | Citations (PDF) |
| 107 | Risk for Life-Threatening Cardiac Events in Patients With Genotype-Confirmed Long-QT Syndrome and Normal-Range Corrected QT Intervals | 2.3 | 297 | Citations (PDF) |
| 108 | Risk Factors for Recurrent Syncope and Subsequent Fatal or Near-Fatal Events in Children and Adolescents With Long QT Syndrome | 2.3 | 115 | Citations (PDF) |
| 109 | Calmodulin kinase II inhibition prevents arrhythmias in RyR2R4496C+/− mice with catecholaminergic polymorphic ventricular tachycardia | 3.8 | 113 | Citations (PDF) |
| 110 | HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies: This document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA) | 2.0 | 749 | Citations (PDF) |
| 111 | ST-Segment Elevation in the Setting of a Febrile Illness 2011, 16, 303-307 | | 3 | Citations (PDF) |
| 112 | Screening for Sudden Cardiac Death in the Young | 18.1 | 146 | Citations (PDF) |
| 113 | Barriers to implementation of evidence-based electrical therapies and the need for outcome research: role of European registries | 2.0 | 24 | Citations (PDF) |
| 114 | The European cardiac resynchronization therapy survey: patient selection and implantation practice vary according to centre volume | 2.0 | 28 | Citations (PDF) |
| 115 | Genetics of sudden death: focus on inherited channelopathies | 2.2 | 113 | Citations (PDF) |
| 116 | Inherited Dysfunction of Sarcoplasmic Reticulum Ca
<sup>2+</sup>
Handling and Arrhythmogenesis | 13.2 | 425 | Citations (PDF) |
| 117 | When is genetic testing useful in patients suspected to have inherited cardiac arrhythmias? | 1.6 | 9 | Citations (PDF) |
| 118 | Identification of circulating placental mRNA in maternal blood of pregnancies affected with fetal congenital heart diseases at the second trimester of pregnancy: implications for early molecular screening | 2.3 | 32 | Citations (PDF) |
| 119 | Purkinje Cells From RyR2 Mutant Mice Are Highly Arrhythmogenic But Responsive to Targeted Therapy | 13.2 | 98 | Citations (PDF) |
| 120 | The Fifteen Years of Discoveries That Shaped Molecular Electrophysiology | 13.2 | 36 | Citations (PDF) |
| 121 | In the RyR2
<sup>R4496C</sup>
Mouse Model of CPVT, β-Adrenergic Stimulation Induces Ca Waves by Increasing SR Ca Content and Not by Decreasing the Threshold for Ca Waves | 13.2 | 97 | Citations (PDF) |
| 122 | Na+-dependent SR Ca2+ overload induces arrhythmogenic events in mouse cardiomyocytes with a human CPVT mutation | 5.5 | 82 | Citations (PDF) |
| 123 | 2010 Focused Update of ESC Guidelines on device therapy in heart failure | 2.0 | 299 | Citations (PDF) |
| 124 | Magnetic resonance investigations in Brugada syndrome reveal unexpectedly high rate of structural abnormalities | 2.2 | 164 | Citations (PDF) |
| 125 | The European cardiac resynchronization therapy survey | 2.2 | 221 | Citations (PDF) |
| 126 | High Efficacy of β-Blockers in Long-QT Syndrome Type 1 | 18.1 | 293 | Citations (PDF) |
| 127 | Increased Ca
<sup>2+</sup>
Sensitivity of the Ryanodine Receptor Mutant RyR2
<sup>R4496C</sup>
Underlies Catecholaminergic Polymorphic Ventricular Tachycardia | 13.2 | 140 | Citations (PDF) |
| 128 | The Long QT Syndrome and Catecholaminergic Polymorphic Ventricular Tachycardia* | 1.1 | 8 | Citations (PDF) |
| 129 | Ryanodine receptor and calsequestrin in arrhythmogenesis: What we have learnt from genetic diseases and transgenic mice | 3.8 | 62 | Citations (PDF) |
| 130 | Clinical Implications for Patients With Long QT Syndrome Who Experience a Cardiac Event During Infancy | 2.3 | 89 | Citations (PDF) |
| 131 | Catecholaminergic polymorphic ventricular tachycardia: A paradigm to understand mechanisms of arrhythmias associated to impaired Ca2+ regulation | 2.7 | 110 | Citations (PDF) |
| 132 | Catecholaminergic Polymorphic Ventricular Tachycardia | 5.7 | 167 | Citations (PDF) |
| 133 | ESC Guidelines for the Diagnosis And Treatment of Acute And Chronic Heart Failure 2008 | 0.5 | 12 | Citations (PDF) |
| 134 | Risk of death in the long QT syndrome when a sibling has died | 2.7 | 66 | Citations (PDF) |
| 135 | Magnetic resonance imaging in individuals with cardiovascular implantable electronic devices | 2.0 | 233 | Citations (PDF) |
| 136 | Long-QT Syndrome After Age 40 | 18.1 | 144 | Citations (PDF) |
| 137 | Risk Factors for Aborted Cardiac Arrest and Sudden Cardiac Death in Children With the Congenital Long-QT Syndrome | 18.1 | 273 | Citations (PDF) |
| 138 | Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) | 2.2 | 1,145 | Citations (PDF) |
| 139 | Clinical diagnosis of long QT syndrome: back to the caliper | 2.2 | 19 | Citations (PDF) |
| 140 | Disruption of calcium homeostasis and arrhythmogenesis induced by mutations in the cardiac ryanodine receptor and calsequestrin | 5.5 | 53 | Citations (PDF) |
| 141 | Outcome parameters for trials in atrial fibrillation: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association | 2.0 | 277 | Citations (PDF) |
| 142 | Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) | 0.1 | 42 | Citations (PDF) |
| 143 | Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) | 2.2 | 989 | Citations (PDF) |
| 144 | Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts) | 2.2 | 363 | Citations (PDF) |
| 145 | Arrhythmogenic Mechanisms in a Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia | 13.2 | 269 | Citations (PDF) |
| 146 | Long QT Syndrome in Adults | 2.3 | 384 | Citations (PDF) |
| 147 | Cardiovascular risks of atypical antipsychotic drug treatment | 1.9 | 66 | Citations (PDF) |
| 148 | Molecular and Electrophysiological Bases of Catecholaminergic Polymorphic Ventricular Tachycardia | 2.1 | 115 | Citations (PDF) |
| 149 | Outcome parameters for trials in atrial fibrillation: executive summary: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA) | 2.2 | 344 | Citations (PDF) |
| 150 | ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death | 2.3 | 1,325 | Citations (PDF) |
| 151 | Arrhythmogenic Mechanism of Catecholaminergic Polymorphic Ventricular Tachycardia | 1.3 | 4 | Citations (PDF) |
| 152 | Estrategias actuales para reducir el impacto de las enfermedades cardiovasculares en la mujer | 1.1 | 5 | Citations (PDF) |
| 153 | Gene-specific therapy for inherited arrhythmogenic diseases 2006, 110, 1-13 | | 25 | Citations (PDF) |
| 154 | Risk of Aborted Cardiac Arrest or Sudden Cardiac Death During Adolescence in the Long-QT Syndrome | 16.6 | 271 | Citations (PDF) |
| 155 | Improving patient access to novel medical technologies in Europe | 2.2 | 6 | Citations (PDF) |
| 156 | Female Predominance and Transmission Distortion in the Long-QT Syndrome | 34.6 | 82 | Citations (PDF) |
| 157 | Arrhythmogenesis in Catecholaminergic Polymorphic Ventricular Tachycardia | 13.2 | 302 | Citations (PDF) |
| 158 | ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death | 18.1 | 1,057 | Citations (PDF) |
| 159 | Recommendations for participation in competitive sport and leisure-time physical activity in individuals with cardiomyopathies, myocarditis and pericarditis | 2.2 | 151 | Citations (PDF) |
| 160 | ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart R | 2.0 | 557 | Citations (PDF) |
| 161 | C-terminal HERG (LQT2) mutations disrupt IKr channel regulation through 14-3-3ϵ | 2.9 | 52 | Citations (PDF) |
| 162 | Genetic Testing in the Long QT Syndrome | 16.6 | 430 | Citations (PDF) |
| 163 | Evidence-based vs. ‘impressionist’ medicine: how best to implement guidelinesThe opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology. | 2.2 | 36 | Citations (PDF) |
| 164 | Evidence-based vs. 'impressionist' medicine: how best to implement guidelines: reply | 2.2 | 0 | Citations (PDF) |
| 165 | Gender-specific prescription for cardiovascular diseases? | 2.2 | 35 | Citations (PDF) |
| 166 | Recommendations for competitive sports participation in athletes with cardiovascular disease: A consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology | 2.2 | 917 | Citations (PDF) |
| 167 | Cardiac and skeletal muscle disorders caused by mutations in the intracellular Ca2+ release channels | 10.6 | 89 | Citations (PDF) |
| 168 | Left Cardiac Sympathetic Denervation in the Management of High-Risk Patients Affected by the Long-QT Syndrome | 18.1 | 643 | Citations (PDF) |
| 169 | Inherited Arrhythmogenic Diseases | 13.2 | 82 | Citations (PDF) |
| 170 | From trials to guidelines to clinical practice: the need for improvement | 2.0 | 3 | Citations (PDF) |
| 171 | Genetics of Cardiac Arrhythmias and Sudden Cardiac Death | 4.0 | 81 | Citations (PDF) |
| 172 | Short Coupled Premature Ventricular Contraction Initiating Ventricular Fibrillation in a Patient with Brugada Syndrome | 2.1 | 10 | Citations (PDF) |
| 173 | Policy Statement | 2.8 | 29 | Citations (PDF) |
| 174 | Risk Stratification in the Long-QT Syndrome | 34.6 | 1,373 | Citations (PDF) |
| 175 | Title is missing! | 1.9 | 34 | Citations (PDF) |
| 176 | Location of Mutation in the KCNQ1 and Phenotypic Presentation of Long QT Syndrome | 2.1 | 70 | Citations (PDF) |
| 177 | Modulating effects of age and gender on the clinical course of long QT syndrome by genotype | 2.3 | 263 | Citations (PDF) |
| 178 | Management of Grown Up Congenital Heart Disease | 2.2 | 461 | Citations (PDF) |
| 179 | Mechanisms of Actions of Inhaled Anesthetics | 34.6 | 10 | Citations (PDF) |
| 180 | Medical Practice Guidelines Separating science from economics | 2.2 | 32 | Citations (PDF) |
| 181 | Involvement of the cardiac ryanodine receptor/calcium release channel in catecholaminergic polymorphic ventricular tachycardia | 4.1 | 188 | Citations (PDF) |
| 182 | Long QT syndrome, Brugada syndrome, and conduction system disease are linked to a single sodium channel mutation | 10.6 | 187 | Citations (PDF) |
| 183 | Long QT syndrome, Brugada syndrome, and conduction system disease are linked to a single sodium channel mutation | 10.6 | 115 | Citations (PDF) |
| 184 | Long QT syndrome, Brugada syndrome, and conduction system disease are linked to a single sodium channel mutation | 10.6 | 27 | Citations (PDF) |
| 185 | Carbon Monoxide Cardiotoxicity | 1.4 | 107 | Citations (PDF) |
| 186 | Cardiac Damage in Pediatric Carbon Monoxide Poisoning | 1.4 | 25 | Citations (PDF) |
| 187 | Foretelling the Future in Brugada Syndrome: Do We Have the Crystal Ball? | 2.1 | 16 | Citations (PDF) |
| 188 | Variable Expression of Long QT Syndrome Among Gene Carriers from Families with Five Different HERG Mutations | 1.0 | 34 | Citations (PDF) |
| 189 | Spotlight on sudden cardiac death | 5.5 | 0 | Citations (PDF) |
| 190 | How should we detect and manage failed thrombolysis? | 2.2 | 8 | Citations (PDF) |
| 191 | Long QT and Brugada Syndromes: From Genetics to Clinical Management | 2.1 | 23 | Citations (PDF) |
| 192 | Clinical and genetic variables associated with acute arousal and nonarousal-related cardiac events among subjects with the long QT syndrome | 1.8 | 74 | Citations (PDF) |
| 193 | Brugada syndrome and sudden death | 2.2 | 10 | Citations (PDF) |
| 194 | A reply | 2.2 | 2 | Citations (PDF) |
| 195 | Exploring the Hidden Danger of Noncardiac Drugs | 2.1 | 42 | Citations (PDF) |
| 196 | Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia | 2.9 | 331 | Citations (PDF) |
| 197 | Lack of correlation between occlusion and reperfusion arrhythmias in the cat | 2.9 | 11 | Citations (PDF) |
| 198 | Nutritional Factors and Arrhythmic Risk in Long QT Syndrome: A Narrative Review of Mechanistic and Clinical Evidence | 7.7 | 0 | Citations (PDF) |
